p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

Döhner, H.; Fischer, Konstanze; Bentz, Martin; Würgler Hansen, Klavs; Benner, Axel; Cabot, G; Diehl, Daniela; F. Schlenk, Richard; Coy, Johannes; Stilgenbauer, Stephan; Volkmann, Martin; R. Galle, Peter; J. Poustka, Albert; Hunstein, W.; Lichter, Peter

doi:10.1182/blood.v85.6.1580.bloodjournal8561580

Public

p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias

Published in Blood • Mar 15, 1995

Authors:

H. Döhner

Konstanze Fischer

Martin Bentz

Abstract

Conventional cytogenetic analysis in B-cell chronic lymphocytic leukemia (B-CLL) has been very difficult, and the prognostic significance of specific chromosome aberrations is under discussion. Recent improvements in fluorescence in situ hybridization (ISH) techniques have provided an alternative ap...

Subject

Chronic lymphocytic leukemia

Fludarabine

Fluorescence in situ hybridization

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!